News
Current Press Releases
September 12, 2024
MBX Biosciences Announces Pricing of Initial Public Offering
September 9, 2024
MBX Biosciences Announces Launch of Initial Public Offering
August 12, 2024
MBX Biosciences Doses First Patient in Phase 2 Avail™ Trial of MBX 2109 for the Treatment of Hypoparathyroidism
August 5, 2024
MBX Biosciences Raises $63.5 Million in Series C Financing to Advance Precision Endocrine Peptide™ (PEP™) Platform
June 25, 2024
MBX Biosciences Appoints Salomon Azoulay, M.D., as Chief Medical Officer
February 5, 2024
MBX Biosciences Appoints Steven Ryder, M.D., to Board of Directors
January 31, 2024
MBX Biosciences to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference
December 20, 2023
MBX Biosciences to Participate in 42nd Annual J.P. Morgan Healthcare Conference
November 1, 2023
MBX Biosciences Announces Appointment of Michelle Graham as Chief Human Resources Officer
October 31, 2023
MBX Biosciences to Participate in Stifel 2023 Healthcare Conference
October 16, 2023
MBX Biosciences Presents Positive Results from Phase 1 Study of MBX 2109 in Late-Breaking Oral Presentation at the American Society for Bone and Mineral Research Annual Meeting
October 9, 2023
MBX Biosciences Doses First Participant in Phase 1/2 Clinical Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
October 3, 2023
MBX Biosciences to Showcase Results from Phase 1 Study of MBX 2109 in Late-Breaking Oral Presentation at the American Society for Bone and Mineral Research Annual Meeting
September 11, 2023
MBX Biosciences Announces Positive Phase 1 Multiple Ascending Dose Data for MBX 2109, a Long-Acting Parathyroid Hormone Peptide Prodrug, in Healthy Adults
August 29, 2023
MBX Biosciences to Participate in Morgan Stanley Global Healthcare Conference
August 7, 2023
MBX Biosciences Announces U.S. FDA Clearance of IND Application for MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
July 10, 2023
MBX Biosciences Appoints Steven J. Prestrelski, Ph.D., M.B.A., as Chief Scientific Officer
May 8, 2023
MBX Biosciences to Participate in May Investor Conferences
April 10, 2023
MBX Biosciences to Participate in the Needham 22nd Annual Healthcare Conference
January 24, 2023
MBX Biosciences to Participate in the SVB Securities Global Biopharma Conference
January 4, 2023
MBX Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
November 14, 2022
MBX Biosciences Closes $115 Million Series B Financing to Advance Development of Endocrine Disease Programs
October 5, 2022
MBX Biosciences Advances Phase 1 Clinical Trial of Long-Acting Parathyroid Hormone Peptide Prodrug, MBX 2109
July 26, 2022
MBX Biosciences Receives Orphan Drug Designation for Lead Candidate MBX 2109 for the Treatment of Hypoparathyroidism
April 11, 2022
MBX Biosciences Appoints Richard B. Bartram as Chief Financial Officer
April 5, 2022
MBX Biosciences Appoints Ora Hirsch Pescovitz, M.D., to Board of Directors
January 5, 2021
MBX Biosciences Appoints Mary Jane Geiger, M.D., Ph.D., as Chief Medical Officer
October 27, 2020
MBX Biosciences Appoints James Cornelius to its Board of Directors
July 27, 2020
MBX Biosciences Closes $34.6 Million Series A Financing in Rare Endocrine Diseases
News Archive
Media Contact
Kate Burdick
Inizio Evoke Communications
[email protected]
860-462-1569
Investor Relations Contact
Irina Koffler
LifeSci Advisors
[email protected]
917-734-7387